Skip Nav Destination
Issues
1 February 2011
-
Cover Image
Cover Image
The cover features a photomicrograph (200X magnification) of a frozen cross-section of laboratory-generated human skin containing a melanocytic lesion created from a cell line obtained from a patient having an early-stage melanoma. This model represents organotypic skin, to which topical agents can be applied for cancer prevention studies that recapitulate results of agents applied to animal skin. The organotypic skin contains layers and boundaries (an epidermis and dermis) similar to those in human skin. Furthermore, green fluorescence protein (GFP)-tagged WM35 cells form an early melanocytic lesion in this model that is similar in structure to that seen in humans with disease at the same stage of development. The GFP-tag in the cells enables measurement via fluorescence microscopy of the effects of topically applied chemopreventive agents. The photomicrograph shows the GFP-tagged melanocytic lesion cells (green) and DAPI-stained nuclei (blue) of these cells, as well as nuclei of keratinocytes and fibroblasts present in the organotypic skin, six days after creation. As reported in this issue of the journal, the chemopreventive efficacy of topically applied ISC-4 was evaluated in this model and compared with its effects in animals with invasive subcutaneous human melanoma xenografts. Cumulatively applied ISC-4 reduced melanocytic or melanoma lesions in the organotypic skin model by 80%90% and similarly decreased tumor development in animals by ∼80%. See article by Nguyen et al. (beginning on page 248) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Perspective
Minireview
Research Articles
Characterization of the Methylation Patterns in Human Papillomavirus Type 16 Viral DNA in Head and Neck Cancers
Il-Seok Park; Xiaofei Chang; Myriam Loyo; Gaosong Wu; Alice Chuang; Myoung Sook Kim; Young Kwang Chae; Sofia Lyford-Pike; William H. Westra; John R. Saunders; David Sidransky; Sara Isabel Pai
Inhibition of EGFR-STAT3 Signaling with Erlotinib Prevents Carcinogenesis in a Chemically-Induced Mouse Model of Oral Squamous Cell Carcinoma
Rebecca J. Leeman-Neill; Raja R. Seethala; Shivendra V. Singh; Maria L. Freilino; Joseph S. Bednash; Sufi M. Thomas; Mary C. Panahandeh; William E. Gooding; Sonali C. Joyce; Mark W. Lingen; Daniel B. Neill; Jennifer R. Grandis
Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention
Paul J. Limburg; Michelle R. Mahoney; Katie L. Allen Ziegler; Stephen J. Sontag; Robert E. Schoen; Richard Benya; Michael J. Lawson; David S. Weinberg; Elena Stoffel; Michael Chiorean; Russell Heigh; Joel Levine; Gary Della'Zanna; Luz Rodriguez; Ellen Richmond; Christopher Gostout; Sumithra J. Mandrekar; Thomas C. Smyrk; for the Cancer Prevention Network
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.